Evidence map›Paper›PMID 40764355›Full record

Observational studyTranslational psychiatry2025

Dynamic neural network modulation associated with rumination in major depressive disorder: a prospective observational comparative analysis of cognitive behavioral therapy and pharmacotherapy.

Nariko Katayama, Kazushi Shinagawa, Jinichi Hirano, Yuki Kobayashi, Atsuo Nakagawa, Satoshi Umeda, Kei Kamiya, Miyuki Tajima, Mizuki Amano, Waka Nogami and 6 more

Abstract readObservational StudyComparative Study
In one paragraph

Observational study in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nariko KatayamaDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan. narikoktym@keio.jp.ORCID http://orcid.org/0000-0003-2103-0287
Kazushi ShinagawaDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4900-397X
Jinichi HiranoDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.
Yuki KobayashiDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.
Atsuo NakagawaDepartment of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Japan.ORCID http://orcid.org/0000-0002-2294-2571
Satoshi UmedaDepartment of Psychology, Keio University Faculty of Letters, Tokyo, Japan.
Kei KamiyaDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.
Miyuki TajimaDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.
Mizuki AmanoDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.
Waka NogamiDepartment of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Japan.
Sakae IharaDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.
Sachiko NodaDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0009-0008-4969-8688
Yuri TerasawaDepartment of Psychology, Keio University Faculty of Letters, Tokyo, Japan.
Toshiaki KikuchiDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.
Masaru MimuraDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.
Hiroyuki UchidaDepartment of Neuropsychiatry Keio University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0628-7036

Funding

Japan Agency for Medical Research and Development (AMED) JP21dm0307102Japan Agency for Medical Research and Development (AMED) JP22dk0307108Japan Agency for Medical Research and Development (AMED) JP25dk0307133MEXT | Japan Society for the Promotion of Science (JSPS) JP21K15717MEXT | Japan Society for the Promotion of Science (JSPS) JP24K18723Takeda Medical Research Foundation 2022
6 · The paper itself

Abstract

Cognitive behavioral therapy (CBT) and pharmacotherapy are primary treatments for major depressive disorder (MDD). However, their differential effects on the neural networks associated with rumination, or repetitive negative thinking, remain poorly understood. This study included 135 participants, whose rumination severity was measured using the rumination response scale (RRS) and whose resting brain activity was measured using functional magnetic resonance imaging (fMRI) at baseline and after 16 weeks. MDD patients received either standard CBT based on Beck's manual (n = 28) or pharmacotherapy (n = 32). Using a hidden Markov model, we observed that MDD patients exhibited increased activity in the default mode network (DMN) and decreased occupancies in the sensorimotor and central executive networks (CEN). The DMN occurrence rate correlated positively with rumination severity. CBT, while not specifically designed to target rumination, reduced DMN occurrence rate and facilitated transitions toward a CEN-dominant brain state as part of broader therapeutic effects. Pharmacotherapy shifted DMN activity to the posterior region of the brain. These findings suggest that CBT and pharmacotherapy modulate brain network dynamics related to rumination through distinct therapeutic pathways.

Indexed as

Antidepressive AgentsBrainCognitive Behavioral TherapyDefault Mode NetworkMajor Depressive DisorderNerve NetRumination, CognitiveAdultFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesAntidepressive Agents

Identifiers

PMID40764355
PMCPMC12325608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.